Characterizing Variants of Unknown Significance of the PTEN tumour suppressor Homolog DAF-18

Glafira Ermakova¹, Chadwick Hou¹, Jeffrey Boudreau¹, William G Bendena¹, Ian D Chin-Sang¹

¹Queen’s University, Department of Biology, Kingston ON Canada

Abstract

Insulin and insulin-like growth factor signaling (IIS) is an anabolic pathway conserved among humans and Caenorhabditis elegans. In humans, the tumour suppressor protein Phosphatase and Tensin Homolog (PTEN) inhibits IIS, preventing excessive growth. PTEN variants are associated with disease, but how they affect PTEN function is not well understood. Here, we characterized variants of unknown significance (VUSs) implicated in autism spectrum disorder by studying homologous mutations in the C. elegans protein DAF-18 to infer how they play a role in human disease. We found that variants D66E and L115V are likely benign, H168Q is intermediate while variants H138R and T176I are likely pathogenic.

Figure 1. Variants of DAF-18 and their respective phenotypes.

A) Structure of the human PTEN protein. Mutations D22E, L70V, H93R, H123Q, and T131I are illustrated with red.

B) Structure of the C. elegans DAF-18 protein. Conserved DAF-18 mutations based on the PTEN variants, D66E, L115V, H138R, H168Q, and T176I in the phosphatase domain are illustrated with red. Adapted from Liu et. al. (2013), and Dirican & Akkiprik (2017).

C) The graph shows the percentage of animals that enter dauer diapause after being exposed to dauer-inducing conditions (48 hours at 27 °C) in wild type, daf-18(qu52) knockout, and daf-18 VUS strains. Graph shows mean ±
Description

Phosphatase and Tensin Homolog (PTEN) acts as a key suppressor of the insulin signaling pathway and thus regulates cell growth and development (Leslie et al., 2008). In humans, this protein still has numerous clinically important variants of unknown significance (VUS) which are implicated in disorders such as autism spectrum disorder (ASD) and are classified as neither pathogenic nor benign (Yehia et al., 2020). Our research aims to classify five of these variants previously implicated in ASD using the model organism Caenorhabditis elegans (C. elegans) (Wong et al., 2019). The insulin pathway is well conserved across metazoans, and thus using this model organism is advantageous as this allows us to characterize PTEN variants by studying its C. elegans homolog DAF-18 (Post et al., 2020). In 2019, Wong et al. characterized DAF-18 variants D66E, L115V, H138R, H168Q, and T176I, which correspond to PTEN variants D22E, L70V, H93R, H123Q, and T131I implicated in ASD (Figure 1A-B). Their analysis focused on morphology and locomotion defects, while González-Cavazos et al. in 2019 studied the effects of these variants on dauer entry. Our work aimed not only to replicate the results found by González-Cavazos et al., 2019 but also to characterize the DAF-18 variants with three new assays: L1 arrest survival, Q-cell division in L1 arrest, and rate of pharyngeal pumping off-food.

C. elegans enter dauer diapause under stressful conditions (such as crowding, starvation, and high temperature), which is typically accompanied by decreased insulin signaling (Karp, 2018). Measuring dauer entry is an effective way to indirectly assess the extent of activation of the insulin signaling pathway. In our work, we exposed C. elegans to high temperature (27 °C) for 48 hours, and dauer entry of wild type, daf-18 knockout (qu52), daf-18(sy879)[D66E], daf-18(sy887)[L115V], daf-18(sy881)[H138R], daf-18(sy885)[H168Q], and daf-18(sy882)[T176I] strain were observed. Results published by González-Cavazos et al., 2019 using dauer pheromone to induce dauer showed that variants daf-18(sy879)[D66E], daf-18(sy887) [L115V] and daf-18(sy885)[H168Q] were similar to wild type worms, whereas daf-18(sy881)[H138R] and daf-18(sy882) [T176I] variants were more dauer defective compared to wild type, with daf-18(sy882)[T176I] showing a stronger phenotype than daf-18(sy881)[H138R]. In our studies, we found that the daf-18(sy879)[D66E] and daf-18(sy887)[H115V] strains resembled wild type in terms of dauer entry, whereas daf-18(sy885)[H168Q], and daf-18(sy882)[T176I] were more dauer defective (Figure 1C). Overall, our findings mostly agreed with published data, with the exception of the daf-18(sy885) [H168Q] strain, though it did have more dauer entry than the dauer defective daf-18(q52) control (Figure 1C).

Measuring L1 arrest survival is another way to assess activation of the insulin signaling pathway, with increased insulin signaling leading to shortened survival (Baugh et al., 2006; Chen et al., 2022). We thus assessed the L1 arrest survival ability of the VUS strains compared to wild type and daf-18(q52) controls. Figure 1D shows the daf-18(sy879)[D66E] is not significantly different from wild type which further classifies this variant as most benign. The daf-18(sy887)[L115V], and daf-18(sy885)[H168Q] live longer in L1 arrest than the daf-18(q52) knockout and therefore are intermediate and not likely null alleles. The daf-18(sy881)[H138R] and daf-18(sy882)[T176I] worms have similar L1 arrest survival to that of the daf-18(q52) knockout strain, with daf-18(sy881)[H138R] not being significantly different from the daf-18(q52) knockout (One-way ANOVA, p=0.9706). This fits in with the published data and further characterizes D66E, L115V, and H168Q variants as benign and H138R and T176I as pathogenic (González-Cavazos et al., 2019). This assay reveals potential phenotype uncoupling with the daf-18(T176I) being more dauer defective than the daf-18(sy881)[H138R] strain, while having a higher survival in L1 arrest (One-way ANOVA p=0.0283).

Another readout of inappropriate activation of IIS in L1 arrest is the presence of divided, fluorescently tagged neuroblast precursor “Q-cells” (Zheng et al., 2018). We thus quantified Q cell division during L1 arrest of the VUS strains compared to wild type and daf-18(q52) controls. Our experiments once again supported daf-18(sy879)[D66E], daf-18(sy887)[L115V], and
**Methods**

*C. elegans* growth conditions: *C. elegans* strains were grown on standard nematode growth medium agar plates (NGM) seeded with 100ml saturated culture *Escherichia coli* (E. coli) OP50 bacteria. Worms were kept in 20 °C at all times except during counting or unless stated otherwise.

Dauer assay: 100-150 synchronized L1 larvae were plated on seeded NGM plates and kept at 27 °C for 48 hours to induce dauer (for details, see Ailion & Thomas, 2000). SDS selection (1% SDS for 30 minutes) was then used to identify dauer and non-dauer worms, as non-dauer worms are killed by the SDS solution. The dauer vs. non-dauer (dead) animals were then manually counted. Three repeats of dauer vs. non-dauer count were done for each strain.

L1 arrest survival assay: *C. elegans* were placed in L1 arrest though sodium hypochlorite treatment and kept in 1.5ml tubes in M9 buffer on a rotator at 20 °C. M9 concentration was adjusted on day 1 of L1 arrest to obtain 10-15 worms per 1ml. Aliquots of 10ml were taken daily to count alive versus dead *C. elegans* (n=100-150 on each day). Three repeats were done for each strain. Statistics were carried out using GraphPad Prism software version 9.

Q-cell division assay: *C. elegans* were placed in L1 arrest using the methods described above. Q-cell division was scored manually throughout days 5-8 of L1 arrest by taking 10ml daily and counting the proportion of *C. elegans* with divided Q-cells (n=100-150 on each day). Division was visualized through a tagging the promoter of a protein expressed in the touch neurons (Pmec-4::GFP), and recording presence of the Q-cell descendant neuron, AVM (Zheng et al., 2018). Three repeats were done for each strain.

Off-food pharyngeal pumping assay: 100-150 synchronized day 1 adult *C. elegans* were washed three times with M9 buffer to remove bacteria. They were then plated onto NGM plates with no bacteria and pharyngeal pumping was manually measured (number of pumps per 10 seconds) after a 1-hour adjustment period.

Reagents

**Strains:**

**daf-18** variants displaying a more benign phenotype while *daf-18(sy881)[H138R]* and *daf-18(sy882)[T176I]* variants were more pathogenic. Figure 1E shows that the *daf-18(sy881)[H138R]* and *daf-18(sy882)[T176I]* variants had some Q-cell division, which is indicative of an overactive IIS in L1 arrest and supports the deleterious effect of these variants. Notably, the phenotypes of *daf-18(sy881)[H138R]* and *daf-18(sy882)[T176I]* variants were not as strong as the *daf-18(qu52)* knockout control, which shows up to 100% Q-cell division in L1 arrest, suggesting that these variants are not completely null for *daf-18* function.

Pharyngeal pumping can be used to measure food intake, which is increased during IIS activation in *C. elegans* (Avery & You, 2018). Previous research shows that worms with an impaired IIS are unable to cease pumping while off food compared to wild type worms (Dallière et al., 2016). We thus quantified the pharyngeal pumping rate of the five DAF-18 VUS strains when taken off the food. We found that the *daf-18* knockout *C. elegans* had a higher pharyngeal pumping rate when taken off food (Figure 1F), as published. Of the VUS strains, *daf-18(sy879)[D66E], daf-18(sy887)[L115V], daf-18(sy885)[H168Q],* and *daf-18(sy882)[T176I]* were similar to wild type, whereas *daf-18(sy881)[H138R]* variant resembled the *daf-18* knockout (Figure 1F). This mostly supports our classification of *daf-18(sy879)[D66E], daf-18(sy887)[L115V],* and *daf-18(sy885)[H168Q]* as benign and *daf-18(sy881)[H138R]* and *daf-18(sy882)[T176I]* as potentially pathogenic, except for *daf-18(sy882)[T176I]*, which could be due to phenotype uncoupling.

Together, the dauer entry, L1 arrest survival, Q-cell division in L1 arrest, and off-food pharyngeal pumping assays show that the D66E variant is most likely benign, being similar to wild type in all experiments. The L115V is also likely benign, being like wild type in 3 of the 4 assays. Meanwhile the H168Q variant appears to be intermediate in terms of its pathogenicity, showing phenotypic defects in half of the experiments. T176I is a stronger variant, with the *daf-18(sy882)[T176I]* allele conferring defects in all but the pharyngeal pumping assay. Meanwhile, the strongest allele appeared to be *daf-18(sy881)[H138R]*, being significantly more deficient than wild type in all assays, and even being similar to the *daf-18(qu52)* knockout when it came to L1 arrest survival and pharyngeal pumping. Future work involving structural analysis of these variants could complement our findings. Furthermore, assessing VUSs of PTEN could be done without first needing to find and create homologous DAF-18 variants through replacement of *daf-18* with different variants of human PTEN via CRISPR. Our research thus helped characterize PTEN variants and has laid the groundwork for analyzing future clinically significant variants.
| Strain # | Genotype | Description |
|----------|----------|-------------|
| N2       | Wild type | Wild isolate from Bristol |
| IC83     | zdIs5 [Pmec-4::GFP+lin-15(+)] I | Touch neurons expressing GFP to visualize AVM and PVM (Q-cell descendants) |
| IC2384   | zdIs5 [Pmec-4::GFP+lin-15(+)]I;daf-18(sy879)IIV | Touch neuron marker with DAF-18 variant D66E |
| IC2385   | zdIs5 [Pmec-4::GFP+lin-15(+)]I;daf-18(sy887)IIV | Touch neuron marker with DAF-18 variant L115V |
| IC2386   | zdIs5 [Pmec-4::GFP+lin-15(+)]I;daf-18(sy885)IIV | Touch neuron marker with DAF-18 variant H168Q |
| IC2389   | zdIs5 [Pmec-4::GFP+lin-15(+)]I;daf-18(sy881)IIV | Touch neuron marker with DAF-18 variant H138R |
| IC2388   | zdIs5 [Pmec-4::GFP+lin-15(+)]I;daf-18(sy882)IIV | Touch neuron marker with DAF-18 variant T176I |
| IC2251   | zdIs5 [Pmec-4::GFP+lin-15(+)]I;daf-18(qu52) [GFP(+)::Δ daf-18] IV | Touch neuron marker with daf-18 KO – allele qu52. The daf-18(qu52) allele is a Crispr/Cas9 edited strain where GFP is inserted at the start codon of daf-18 locus, creating a transcriptional reporter and an out of frame daf-18 knock out. Sequences are available upon request. |

**Acknowledgements:** The authors thank Dr. Paul Sternberg and his lab for sharing daf-18 variant alleles used in this study. Some of this material is found in the MSc thesis of Glafira Ermakova.

**References**

Ailion M, Thomas JH. 2000. Dauer formation induced by high temperatures in Caenorhabditis elegans. Genetics 156: 1047-67. PubMed ID: 11063684

Avery L, You YJ. 2012. C. elegans feeding. WormBook : 1-23. PubMed ID: 22628186

Baugh LR, Sternberg PW. 2006. DAF-16/FOXO regulates transcription of cki-1/Cip/Kip and repression of lin-4 during C. elegans L1 arrest. Curr Biol 16: 780-5. PubMed ID: 16631585

Dallière N, Bhatla N, Luedtke Z, Ma DK, Woolman J, Walker RJ, Holden-Dye L, O’Connor V. 2016. Multiple excitatory and inhibitory neural signals converge to fine-tune Caenorhabditis elegans feeding to food availability. FASEB J 30: 836-48. PubMed ID: 26514165
Dirican E, Akkiprik M. 2017. Phosphatidylinositol 3-kinase regulatory subunit 1 and phosphatase and tensin homolog as therapeutic targets in breast cancer. Tumour Biol 39: 1010428317695529. PubMed ID: 28351303

González-Cavazos C, Cao M, Wong WR, Chai C, Sternberg P. 2019. Effects of ASD-associated daf-18/PTEN missense variants on C. elegans dauer development. MicroPubl Biol 2019:10.17912/micropub.biology.000177. PubMed ID: 32550443

Karp X. 2018. Working with dauer larvae. WormBook 2018: 1-19. PubMed ID: 27417559

Leslie NR, Batty IH, Maccario H, Davidson L, Downes CP. 2008. Understanding PTEN regulation: PIP2, polarity and protein stability. Oncogene 27: 5464-76. PubMed ID: 18794881

Liu J, Visser-Grieve S, Boudreau J, Yeung B, Lo S, Chamberlain G, et al., Chin-Sang I. 2014. Insulin activates the insulin receptor to downregulate the PTEN tumour suppressor. Oncogene 33: 3878-85. PubMed ID: 23995781

Post KL, Belmadani M, Ganguly P, Meili F, Dingwall R, McDiarmid TA, et al., Haas K. 2020. Multi-model functionalization of disease-associated PTEN missense mutations identifies multiple molecular mechanisms underlying protein dysfunction. Nat Commun 11:(1), 1-16 PubMed ID: 32350270

Wong WR, Brugman KI, Maher S, Oh JY, Howe K, Kato M, Sternberg PW. 2019. Autism-associated missense genetic variants impact locomotion and neurodevelopment in Caenorhabditis elegans. Hum Mol Genet 28: 2271-2281. PubMed ID: 31220273

Yehia L, Keel E, Eng C. 2020. The Clinical Spectrum of PTEN Mutations. Annu Rev Med 71: 103-116. PubMed ID: 31433956

Zheng S, Qu Z, Zanetti M, Lam B, Chin-Sang I. 2018. C. elegans PTEN and AMPK block neuroblast divisions by inhibiting a BMP-insulin-PP2A-MAPK pathway. Development 145 (23):dev166876. PubMed ID: 30487179

Funding: This work was funded by the Canadian Institutes of Health Research (CIHR; http://www.cihr-irsc.gc.ca/; ICS)

Author Contributions: Glafira Ermakova: formal analysis, writing - original draft, investigation, writing - review editing. Chadwick Hou: investigation. Jeffrey Boudreau: investigation. William G Bendena: writing - review editing. Ian D Chin-Sang: investigation, methodology, supervision, writing - review editing.

Reviewed By: Anonymous

History: Received October 3, 2022 Revision Received November 15, 2022 Accepted November 19, 2022 Published Online November 28, 2022 Indexed December 12, 2022

Copyright: © 2022 by the authors. This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Citation: Ermakova, G; Hou, C; Boudreau, J; Bendena, WG; Chin-Sang, ID (2022). Characterizing Variants of Unknown Significance of the PTEN tumour suppressor. Homolog DAF-18 . microPublication Biology. 10.17912/micropub.biology.000689

11/28/2022 - Open Access